Short Interest in IceCure Medical Ltd (NASDAQ:ICCM) Increases By 5.1%

IceCure Medical Ltd (NASDAQ:ICCM) saw a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 164,300 shares, a growth of 5.1% from the May 31st total of 156,400 shares. Currently, 0.8% of the shares of the stock are short sold. Based on an average trading volume of 405,600 shares, the days-to-cover ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ICCM shares. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of IceCure Medical in a report on Tuesday. Alliance Global Partners boosted their price objective on IceCure Medical from $1.90 to $2.90 and gave the stock a “buy” rating in a report on Wednesday, March 20th.

IceCure Medical Trading Down 0.2 %

NASDAQ ICCM traded down $0.00 on Wednesday, hitting $0.74. 50,869 shares of the company were exchanged, compared to its average volume of 488,316. The company’s 50 day moving average price is $0.97 and its 200-day moving average price is $1.16. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.39 and a quick ratio of 2.88. The firm has a market capitalization of $33.76 million, a P/E ratio of -2.25 and a beta of 0.57. IceCure Medical has a twelve month low of $0.52 and a twelve month high of $1.57.

IceCure Medical (NASDAQ:ICCM) last posted its quarterly earnings data on Tuesday, May 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.80 million. IceCure Medical had a negative return on equity of 101.66% and a negative net margin of 444.30%. During the same quarter in the previous year, the company earned ($0.08) EPS. Analysts predict that IceCure Medical will post -0.28 earnings per share for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.